Financial Daily from THE HINDU group of publications
Thursday, Jun 08, 2006


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Outlook
Web Extras - Pharmaceuticals


Biocon's cancer drug gets `favourable review'

Our Bureau

Drug controller approval pending

Bangalore , June 7

Biocon Ltd's BIOMab EGFR, the first indigenously developed monoclonal antibody used in treating many cancers, has received `favourable review' from the drug regulator. With approval pending, the life-saving drug could be in the market in the next few months, according to Biocon CMD, Ms Kiran Mazumdar-Shaw.

She was speaking at an event in which the President, Mr A.P.J. Abdul Kalam, dedicated to the nation the BIOMab EGFR (epidermal growth factor receptor) and inaugurated the 90-acre, Rs 650-crore Biocon Park, which has received a captive SEZ status.

The monoclonal antibody therapy is considered one of the most promising cancer treatments. The Biocon M A b has been developed over two years with Cuban collaboration. Although M A bs have been introduced in the country, they are not affordable and the home-grown product could make a difference, she said.

Biocon said it joins the exclusive league of monoclonal antibody developers worldwide and aims to be a key player in this segment in the coming years. The President said India had missed the Human Genome Project bus and should now focus on proteomics and the futuristic gene chip-based therapies. Biocon itself should look at low-cost drugs to control HIV and infectious diseases. The new cancer drug can be used to treat cancers of head and neck, colorectal, pancreatic, metastatic breast, non-small cell lung and brain cancers.

The Biocon Park, of which 45 acres have been developed, is the country's largest integrated biotech hub with the single largest capital investment by the company, Ms Mazumdar-Shaw said. It houses the subsidiary Syngene International, Biocon Biopharmaceuticals, which will produce the antibodies in the initial phase. It employs 700 scientists and technical staff and will expand to 2,000.

The park will focus on export of bio-pharmaceutical products and research services for cardiovascular problems, cholesterol reduction, immunosuppressants in organ transplantation, diabetes, and cancer.

More Stories on : Outlook | Bio-tech & Genetics | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
IOC liquidates oil bonds worth Rs 835 cr


Air Deccan on revamp mode
`India cannot survive only as low-cost producer'
Ranbaxy ties up with Zenotech for oncology products
Genetix ties up with Labmate
SJS, Serigraph in joint venture
L&T approves 1:1 bonus issue
REL aims to generate 16,000 MW
Janapriya weighing fund-raising options
Biocon's cancer drug gets `favourable review'
Samtel to increase picture tube output
JCB India aims to boost sales in AP
Who will take over from Murthy in August?



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line